Federal Register / Vol. 76, No. 68 / Friday, April 8, 2011 / Notices 19779 

disabilities, illnesses, conditions, and 

deaths (and their associated time 

frames) associated with each category of 

vaccines included on the Table. See 

sections 2114(c) and 2114(e)(2) of the 

PHS Act, 42 U.S.C. 300aa–14(c) and 

30aa–14(e)(2). Finally, section 

2114(c)(2) of the PHS Act, 42 U.S.C. 

300aa–14(c)(2) provides that: 

[a]ny person (including the Advisory 

Commission on Childhood Vaccines) may 

petition the Secretary to propose regulations 

to amend the Vaccine Injury Table. Unless 

clearly frivolous, or initiated by the 

Commission, any such petition shall be 

referred to the Commission for its 

recommendations. Following— 

(A) receipt of any recommendation of the 

Commission, or 

(B) 180 days after the date of the referral 

to the Commission, whichever occurs first, 

the Secretary shall conduct a rule-making 

proceeding on the matters proposed in the 

petition or publish in the Federal Register a 

statement of reasons for not conducting such 

proceeding. 

On September 9, 2010, a private person 

submitted a petition to amend the Table. 

This petition was submitted to the Chief 

Special Master, Sandra Lord, with a 

copy to Dr. Geoffrey Evans, Director, 

Division of Vaccine Injury 

Compensation. Pursuant to the VICP 

statute, Dr. Evans referred the petition to 

the Commission on October 28, 2010. 

The Commission discussed the petition 

at its meeting on March 3, 2011. At the 

conclusion of this discussion, the 

Commission voted unanimously to 

recommend that the Secretary not 

proceed with rule-making to amend the 

Table as requested in the petition. 

The petition requests that the 

Secretary amend the Table to include 

Guillain-Barre ́ Syndrome (GBS) as an 

injury following certain vaccines. The 

petition asserts that ‘‘[e]very drug 

company admits that GBS is linked to 

many different vaccines including 

influenza, meningitis, and cervical 

cancer [human papillomavirus].’’ The 

petitioner asserts that her mother 

received the seasonal influenza vaccine, 

and was subsequently diagnosed with 

GBS. Other than the assertion cited, the 

petition does not cite scientific support, 

nor indicate specifically for which 

vaccines GBS should be added as an 

injury, nor indicate any appropriate 

time-frame. 

Nonetheless, the Secretary takes very 

seriously proposals to modify the Table. 

Prior to receipt of the petition, in 2008, 

the Secretary contracted with the 

Institute of Medicine (IOM) to review 

the epidemiological, clinical, and 

biological evidence regarding adverse 

health events associated with specific 

vaccines covered by the VICP. The 

vaccines to be reviewed are: 

• Varicella vaccines, 

• influenza vaccines, 

• hepatitis B vaccine, 

• human papillomavirus vaccines, 

• hepatitis A vaccines, 

• meningococcal vaccines, 

• measles-mumps rubella vaccines, 

and 

• diphtheria, tetanus, pertussis 

vaccines. 

The IOM committee will author a 

consensus report with conclusions on 

the evidence bearing on causality and 

the evidence regarding the biological 

mechanisms that underlie specific 

theories for how a specific vaccine is 

related to a specific adverse event. In 

particular, the report will contain 

updated findings on the possible causal 

relationship between certain VICPcovered vaccines and GBS, as well as 

other possible injuries/medical 

conditions. The Secretary expects to 

receive the IOM consensus report in 

early summer. After receipt of the 

consensus report, and a careful analysis 

of the important scientific and policy 

considerations raised by the findings in 

the report, the Secretary will consider 

whether to engage in a rule-making 

proceeding to modify the Table. As 

required by law, any such rule-making 

proceeding would include notice and 

opportunity for a public hearing and at 

least 180 days of public comment. See 

section 2114(c)(1) of the PHS Act, 42 

U.S.C. 300aa–14(c)(1). Also as required 

by law, the Secretary would provide to 

the Commission a copy of the proposed 

regulation or revision, request 

recommendations and comments by the 

Commission, and afford the 

Commission at least 90 days to make 

such recommendations. See section 

2114(d) of the PHS Act, 42 U.S.C. 

300aa–14(d). 

The Secretary intends to consider 

whether to engage in a rule-making 

process with the benefit of the 

important scientific information soon to 

be provided by the IOM; to begin the 

lengthy process without such additional 

information would not result in rulemaking founded on the best and most 

recent scientific knowledge. For these 

reasons, it has been determined not to 

conduct a rule-making proceeding based 

on the petition received at this time. 

Dated: April 1, 2011. 

Mary K. Wakefield, 

Administrator. 

[FR Doc. 2011–8395 Filed 4–7–11; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director; Notice of Charter 

Renewal 

In accordance with Title 41 of the 

U.S. Code of Federal Regulations, 

Section 102–3.65(a), notice is hereby 

given that the Charter for the Center for 

Scientific Review Advisory Council 

(CSRAC), formerly National Institutes of 

Health Peer Review Committee, was 

renewed for an additional two-year 

period on March 31, 2011. 

It is determined that the CSRAC is in 

the public interest in connection with 

the performance of duties imposed on 

the National Institutes of Health by law, 

and that these duties can best be 

performed through the advice and 

counsel of this group. 

Inquiries may be directed to Jennifer 

Spaeth, Director, Office of Federal 

Advisory Committee Policy, Office of 

the Director, National Institutes of 

Health, 6701 Democracy Boulevard, 

Suite 1000, Bethesda, Maryland 20892 

(Mail code 4875), Telephone (301) 496– 

2123, or spaethj@od.nih.gov. 

Dated: April 4, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–8440 Filed 4–7–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 


srobinson on DSKHWCL6B1PROD with NOTICES
19780 Federal Register / Vol. 76, No. 68 / Friday, April 8, 2011 / Notices 

Special Emphasis Panel; NIDDK Genetics 

Repository Contract Technical Application 

Review. 

Date: May 4, 2011. 

Time: 9 a.m. to 12 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892. (Telephone 

Conference Call.) 

Contact Person: Xiaodu Guo, MD, PhD, 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 761, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–4719, 

guox@extra.niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: April 4, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–8435 Filed 4–7–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Translational 

Research. 

Date: May 17, 2011. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Michele L. Barnard, PhD, 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 753, 6707 Democracy Boulevard, 

Bethesda, MD 20892–2542. (301) 594–8898. 

barnardm@extra.niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: April 4, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–8436 Filed 4–7–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Program 

Project: Computational Cellular Imaging. 

Date: May 2–3, 2011. 

Time: 10 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting.) 

Contact Person: Behrouz Shabestari, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5106, 

MSC 7854, Bethesda, MD 20892, (301) 435– 

2409, shabestb@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: April 4, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–8442 Filed 4–7–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Inherited 

Disease Research Access Committee. 

Date: April 29, 2011. 

Time: 8:30 a.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Crowne Plaza Hotel, 8777 Georgia 

Avenue, Silver Spring, MD 20910. 

Contact Person: Camilla E. Day, PhD, 

Scientific Review Officer, CIDR, National 

Human Genome Research Institute, National 

Institutes of Health, 5635 Fishers Lane, Suite 

4075, Bethesda, MD 20892, 301–402–8837, 

camilla.day@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: April 4, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–8437 Filed 4–7–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOUSING AND 

URBAN DEVELOPMENT 

[Docket No. FR–5477–N–14] 

Federal Property Suitable as Facilities 

To Assist the Homeless 

AGENCY: Office of the Assistant 

Secretary for Community Planning and 

Development, HUD. 

ACTION: Notice. 

SUMMARY: This Notice identifies 

unutilized, underutilized, excess, and 

surplus Federal property reviewed by 

HUD for suitability for possible use to 

assist the homeless. 

FOR FURTHER INFORMATION CONTACT: 

Juanita Perry, Department of Housing 

and Urban Development, 451 Seventh 


srobinson on DSKHWCL6B1PROD with NOTICES